ArticleJournal of thoracic disease2025
A phase II clinical trial on the efficacy and safety of carboplatin plus nab-paclitaxel in chemotherapy-naive advanced or recurrent thymic epithelial tumors: protocol of Nab-TET.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Systemic therapy for advanced thymic epithelial tumors: a narrative review of current evidence and perspectives.Mediastinum (Hong Kong, China) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thymic epithelial tumors (TETs) are rare, posing challenges for conducting large-scale clinical trials and leading to slower therapeutic advancements compared with other cancers. Although carboplatin plus paclitaxel therapy is the preferred standard treatment, its clinical use presents challenges, including the frequent occurrence of peripheral neuropathy. In a phase III study, carboplatin plus nab-paclitaxel therapy demonstrated superior efficacy over carboplatin plus paclitaxel therapy in advanced or recurrent non-small cell lung cancer, with reduced adverse events such as peripheral neuropathy, neutropenia, and myalgia. Carboplatin plus nab-paclitaxel therapy has the potential to offer similar efficacy with reduced toxicity in TETs. Therefore, we plan to conduct a phase II clinical trial to clarify the efficacy and safety of carboplatin plus nab-paclitaxel in patients with TETs. Methods: This study plans to enroll 44 patients with advanced or recurrent TETs, with a performance status of 0 or 1, and adequate organ function. Carboplatin (area under the blood concentration-time curve of 5 or 6) will be administered on day 1, while nab-paclitaxel (100 mg/m Discussion: Carboplatin plus nab-paclitaxel therapy may serve as a promising first-line regimen with a relatively mild side-effect profile and expected efficacy in rare TETs. We aim to determine whether this therapy is a better treatment option with lower toxicity. Trial Registration: This clinical trial was registered in the Japan Registry of Clinical Trials (No. jRCTs071240019) on June 6
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.